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PEvaluation of platelet activation in patients supported by the Jarvik
2000* high–rotational speed impeller ventricular assist device
Christoph Lo¨ffler, MD,az Andreas Straub, MD,cz Nicole Bassler, BA,cz Katharina Pernice, MD,b Friedhelm Beyersdorf, MD,b
Christoph Bode, MD,a Michael P. Siegenthaler, MD,bxk and Karlheinz Peter, MDck
Objective: The Jarvik 2000 (Jarvik Heart, Inc, New York, NY) is a thumb-sized high-speed impeller pump that is
used as a ventricular assist device in patients with terminal heart failure. Because the Jarvik 2000 is designed for
long-term use, it is a central question whether the mechanical forces inside the pump affect blood components.
This study evaluated the potential association of the high rotational speed of the Jarvik 2000 with platelet activa-
tion, which may result in thromboembolic events.
Methods: The study group comprised patients with terminal heart failure who were supported with the Jarvik
2000. All were men and received 100 mg aspirin daily. In 8 patients, soluble platelet activation markers (P-selec-
tin and sCD40L), platelet counts, and hemolysis markers (haptoglobin and lactate dehydrogenase levels) were
determined. In 5 patients, P-selectin expression and platelet receptor glycoprotein IIb/IIIa activation were deter-
mined with flow cytometry and compared with a control group of 5 healthy men. Platelet activation was measured
at various rotational device speeds.
Results: After Jarvik 2000 implantation, increased hemolysis was observed, but platelet activation markers and
platelet counts were not affected. Increased rotational speed (8000 to 12,000 rpm) of the device also did not result
in increased platelet activation.
Conclusion: The Jarvik 2000 was not associated with detectable platelet activation, despite high rotational im-
peller speeds.
Cardiopulmonary Support Lo¨ffler et alPatients with congestive heart failure face a limited quality
of life and a decreased life expectancy. Often cardiac trans-
plant remains the ultimate step, despite maximal medical
therapy. The Jarvik 2000 ventricular assist device (Jarvik
Heart, Inc, New York, NY) was developed as a bridge to
transplant but also as a long-term, lifetime mechanical circu-
latory support system for patients ineligible for or unwilling
to undergo transplant. The Jarvik 2000 is a thumb-sized,
silent, titanium, axial-flow impeller pump weighing 90 g,
with a displacement volume of 25 cm3. The pump itself is
implanted into the apex of the failing left ventricle, and a
vascular graft conveys blood to the descending thoracic
aorta or alternatively to the ascending aorta. The impeller
is supported by mechanical bearings and spins within an
electromagnetic field at between 8000 and 12,000 rpm,
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on the systemic vascular resistance.1,2
Major complications of mechanical circulatory support
with rotary blood pumps include bleeding, infection, late
mechanical failure, and thrombembolism.3,4 Because of
the high rotational speed of the impeller pump, blood
elements are exposed to shear stress. Shear forces can cause
activation of platelets, thereby promoting thrombotic
events.5 It is therefore a central question whether platelet
activation occurs in patients after implantation of the Jarvik
2000, because the induction of a prothrombotic state by the
Jarvik 2000 could result in thrombotic and thromboembolic
complications. This point is also of particular interest be-
cause potent antiplatelet drugs are available. We report
here for the first time details about the platelet activation
status in patients with the Jarvik 2000 assist device.
MATERIALS AND METHODS
Patients and Control Subjects
Patient selection. Patients with end-stage heart failure who were not
transplant candidates and had deterioration despite maximal medical treat-
ment were considered for Jarvik 2000 implantation at the University Med-
ical Center Freiburg, Germany. Heart failure criteria for transplantation or
mechanical left ventricular support6 had to be present. Between May
2001 and February 2004, a total of 8 male patients were enrolled in the
study. The patients described in this report did not qualify for heart trans-
plant because of advanced age (1 patient), amyloidosis (1 patient), elevated
pulmonary vascular resistance (4 patients), patient request (1 patient); the
final patient was unsuitable for a conventional left ventricular assist device
because of a small body frame with a body surface area not greater than
1.5 m2. Table 1 lists demographic and preoperative hemodynamic data.urgery c March 2009
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PAbbreviations and Acronyms
ADP ¼ adenosine diphosphate
CI ¼ confidence interval
GP ¼ glycoprotein
LDH ¼ lactate dehydrogenase
All but 1 patient, who had diastolic cardiac failure associated with amyloid-
osis, had either idiopathic dilated cardiomyopathy or ischemic cardiomyop-
athy with chronic heart failure (New York Heart Association functional
class IV) despite maximal medical management. In our protocol, the Jarvik
2000 was not offered to patients with a fixed pulmonary vascular resistance
greater than 7 Wood units because of the high risk of postoperative right
ventricular failure. Inclusion and exclusion criteria for Jarvik implantation
have been previously discussed.7,8
Surgical methods, device management, and follow-up.
In all cases, the device was implanted and postoperative care was performed
in accordance with previously published reports.2,9-11 After the initial post-
operative period, the patients described in this report had anticoagulation
with intravenous heparin; a week after the operation, anticoagulation was
switched to phenprocoumon with the aim of achieving an international nor-
malized ratio between 3.0 and 3.5. Angiotensin-converting enzyme inhibi-
tion and b-blockade were continued to support the native heart function,
because these patients need continuous heart failure treatment and also to
optimize pump flow by lowering systemic vascular resistance. In addition,
all patients received aspirin at 100 mg/d. Patients were discharged home be-
tween 5 and 8 postoperative weeks. Most patients attended a rehabilitation
center for a structured exercise program before returning home. Each patient
was evaluated in a specialized outpatient clinic every 6 to 8 weeks. At these
visits, laboratory and study parameters were evaluated and echocardiogra-
phy was performed to monitor native heart and device function.
Blood sampling. All blood sampling procedures were approved by
the ethics committee of the University Medical Center Freiburg (project
number 58/01). Blood was collected by venipuncture with a 21-gauge but-
terfly needle from an antecubital vein. A 2-mL portion of blood was drawn
and discarded before blood samples for analysis were drawn in further sy-
ringes and anticoagulated with citrate or ethylenediaminetetraacetic acid.
In 8 cases preimplantation as well as postimplantation data were available
for the soluble plasma platelet activation markers P-selectin and soluble
CD40L and for standard laboratory markers. In 5 cases, flow cytometric
data for platelet activation state after Jarvik 2000 implantation were avail-
able. Blood sampling after Jarvik 2000 implantation was performed be-
tween 3 weeks to 11 months after the operation. In some cases, several
blood samples after Jarvik 2000 implantation were available at additional
times. For the data depiction and analysis, data from the sampling point clos-
est to the implantation date are shown.
Control group. We compared the flow cytometric data for platelet P-
selectin expression and glycoprotein (GP) IIb/IIIa activation with normal
platelet activation in 5 healthy men similar in age to the Jarvik patient group.
Flow Cytometry
Samples for flow cytometric analysis were prepared with a whole blood
assay and evaluated according to the principle of a previously described
method.12 Whole blood anticoagulated with citrate was diluted 1:50 with
modified Tyrode’s buffer (150-mmol/L sodium chloride, 2.5-mmol/L potas-
sium chloride, 1.2-mmol/L monosodium carbonate, 2-mmol/L calcium
chloride, 2-mmol/L magnesium chloride, 1-mg/mL bovine serum albumin,
and 1-mg/mL glucose). A 50-mL aliquot of this blood-buffer dilution was
added to 10 mL of the appropriate antibody solution and to 10 mL of the
platelet activator adenosine diphosphate (ADP, final concentrationThe Journal of Thoracic and20 mmol/L; mo¨Lab GmbH, Langenfeld, Germany). In nonstimulated sam-
ples, the ADP solution was replaced with 10 mL of modified Tyrode’s buffer
to achieve equal volumes. After gentle mixing, the samples were incubated
at room temperature for 20 minutes and then diluted with 500 mL of 13
CellFix (BD Biosciences, Heidelberg, Germany) to achieve a stable fixation
and to avoid platelet activation. Flow cytometry was performed on a FACS-
Calibur cytometer (BD Biosciences) within 2 hours after the fixation step.
The instrument was aligned with CaliBrite beads (BD Biosciences). Blood
cells were examined with CellQuest software (BD Biosciences), and plate-
lets were identified by light scatter characteristics. A gate was set around the
platelet population, and platelet identity was confirmed with the anti-GP IIb
antibody SZ22 (Beckman-Coulter GmbH, Krefeld, Germany). A total of
10,000 platelets were analyzed within this gate in each measurement.
Platelet activation status was measured with a phycoerythrin-labeled anti-
body directed against P-selectin (BD Biosciences). The activation status
of GP IIb/IIIa was investigated with the activation-specific fluorescein
isothiocyanate–labeled immunoglobulin M monoclonal antibody PAC-1
(BD Biosciences).
Measurement of Soluble Activation Markers
Soluble P-selectin and soluble CD40L were measured by enzyme-linked
immunosorbent assay (R&D Systems, Inc, Minneapolis, Minn) according
to manufacturer recommendations. For soluble P-selectin, ethylenediamine-
tetraacetic acid–anticoagulated plasma was diluted 1:20, and for CD40L,
ethylenediaminetetraacetic acid–anticoagulated plasma was diluted 1:5;
100 mL diluted plasma was used per well. All measurements were per-
formed in triplicate.
Measurement of Standard Laboratory Parameters
Platelet count, mean corpuscular volume, mean corpuscular hemoglobin
concentration, and international normalized ratio, as well as haptoglobin
and lactate dehydrogenase (LDH) levels, were determined in the clinical
laboratory facilities of the University Medical Center Freiburg, Germany,
according to standard laboratory methods.
Statistics
All data except the haptoglobin values are described by means, with
95% confidence intervals (CIs) or SEs as indicated. The results of the
TABLE 1. Patient demographic characteristics (n ¼ 8)
Mean
95% Confidence
interval Range
Age (y) 61 54.6–67.4 49–74
Body surface area (m2) 2.0 1.8–2.2 1.5–2.3
Duration of heart failure (y) 8.6 3.3–13.8 3–18
Creatinine (mg/dL) 1.2 0.4–1.9 0.3–2.6
Heart failure severity score* 6.4 5.8–6.9 5.4–7.2
Cardiac index (L/[min $ m2]) 2 1.7–2.2 1.5–2.3
Maximal oxygen uptake
(mL/[min $ m2])
11.4 9.8–12.3 7.5–13.9
Pulmonary vascular resistance
(Wood units)
3.4 1.7–5.1 0.8–7
Pulmonary capillary wedge
pressure (mm Hg)
20 13–27 7–33
Left ventricular end-diastolic
diameter (mm)
70.5 56.7–84.3 39–90y
Ejection fraction (%) 22 14–30 15–40y
All patients were male. *See reference 19. yIncludes the values of the patient with
amyloidosis with a small left ventricle, diastolic heart failure, and preserved systolic
function.Cardiovascular Surgery c Volume 137, Number 3 737
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Pflow cytometric measurements of the Jarvik patient group and the control
group were compared with unpaired t tests. The preoperative and postop-
erative values of soluble platelet activation markers, platelet counts, mean
corpuscular volume, and mean corpuscular hemoglobin concentration, as
well as LDH levels, were compared with paired t tests. In 5 cases the
haptoglobin levels after Jarvik implantation were below the detection
limit of the measurement assay (<5 mg/dL). For the statistical analysis,
these values were overestimated as 5 mg/dL, and the group values are
described as medians and ranges. Preoperative and postoperative hapto-
globin values were compared with a 1-sided Wilcoxon matched pairs
test.
RESULTS
P-selectin Expression on Circulating Platelets
The activation status of circulating platelets was deter-
mined by flow cytometry. P-selectin (CD62P) is an adhesion
molecule that is localized in a-granula of non-stimulated
platelets. After stimulation, P-selectin is mobilized to the
cell membrane, and thus its flow cytometric detection on
the platelet surface can be used as marker of platelet activa-
tion. The comparison of 5 Jarvik patients with control sub-
jects did not show a significant increase in P-selectin
expression on platelets in Jarvik patients in either nonstimu-
lated or ADP-stimulated samples (Figure 1).
GP IIb/IIIa Activation on Circulating Platelets
In addition to the surface expression of P-selectin, another
major change in platelets during their activation is a confor-
mational switch of the platelet fibrinogen receptor integrin
GP IIb/IIIa from a low-affinity state to a high-affinity state.
This conformational change can be detected with the mono-
clonal immunoglobulin M antibody PAC-1, which binds
only to the high-affinity GP IIb/IIIa receptor. The compari-
son between control subjects and Jarvik patients did not
demonstrate differences in the binding of PAC-1 on platelets
in either nonstimulated or ADP-stimulated samples (Fig-
ure 2). According to two sensitive parameters, circulating
platelets in patients with the Jarvik 2000 assist device
were not activated.
Platelet Activation Status With Different Rotational
Speeds of the Jarvik 2000 Axial Impeller
To investigate the influences of the Jarvik 2000 impeller
speed and pump flow on platelets, both P-selectin expression
and GP IIb/IIIa activation were determined in 1 patient with
the Jarvik 2000 assist device at five different impeller
FIGURE 1. Platelet activation in Jarvik patients compared with control
subjects. Flow cytometric analysis did not show any difference in binding
of phycoerythrin-labeled antibody against the platelet activation marker
P-selectin (fluorescence in arbitrary units, a.u.) on nonstimulated (n.s.,
P ¼ 0.11 by t test) or on adenosine diphosphate–stimulated (ADP, P ¼
.22 by t test) platelets from 5 male Jarvik patients relative to platelets
from 5 healthy men of similar age. Data are shown as means with 95% con-
fidence intervals.
FIGURE 2. Activation of platelet receptor glycoprotein (GP) IIb/IIIa in
Jarvik patients compared with control subjects. Flow cytometric analysis
with fluorescein isothiocyanate–labeled antibody PAC-1 that binds only
to activated glycoprotein IIb/IIIa showed no differences in activation state
of platelet glycoprotein IIb/IIIa receptor (fluorescence in arbitrary units,
a.u.) in either nonstimulated (n.s., P ¼ .57 by t test) or adenosine diphos-
phate–stimulated (ADP, P ¼ .45 by t test) platelets from 5 Jarvik patients
relative to platelets from 5 healthy men of similar age. Data are shown as
means with 95% confidence intervals.
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Protational speeds. Notably, there were no increases in anti–
P-selectin antibody and PAC-1 antibody binding on platelets
during the stepwise increase of the rotation of the Jarvik ax-
ial impeller pump from 8000 to 12,000 rpm (Figure 3).
Soluble Markers of Platelet Release as Memory of
Platelet Activation
Soluble P-selectin. Because mild activation of platelets
may not be detectable by flow cytometric analysis of circu-
lating platelets, soluble markers of platelet activation were
determined. Soluble P-selectin is shed from the platelet
membrane during platelet activation, and its plasma level
thus is also a marker of platelet activation. There was no dif-
ference in plasma levels of soluble P-selectin after implanta-
tion of the Jarvik 2000 relative to preoperative values
(Figure 4).
Soluble CD40L. CD40L is a membrane molecule that be-
comes mobilized to the platelet surface during platelet acti-
vation. Similar to P-selectin, this molecule is also shed from
the platelet surface and can be detected as soluble CD40L in
plasma. There was no difference in plasma levels of soluble
CD40L after implantation of the Jarvik 2000 relative to pre-
operative values (Figure 4).
An analysis of soluble platelet activation markers in pa-
tients with blood samples from additional time points that
could be analyzed revealed no relationship between platelet
activation and time since the Jarvik 2000 was implanted
(data not shown).
Platelet Counts and Hemolysis
Because the high rotational speed of the impeller pump
may damage corpuscular blood elements, single platelet
counts and potential signs of hemolysis were investigated
in Jarvik patients. There was no statistically significant dif-
ference (P ¼ .8 by paired t test) regarding preoperative
values of single platelet counts (mean 273.3 3 103 cells/
mL, 95% CI 206.7–339.83 103 cells/mL) and postoperative
values (mean 268.13 103 cells/mL, 95% CI 188.9–347.43
103 cells/mL). Haptoglobin levels decreased from a preoper-
ative median of 167 mg/dL (range 50–222 mg/dL) to a post-
operative median of 5 mg/dL (range 5-77 mg/dL, P¼ .008).
There was only a mild and statistically nonsignificant in-
crease (P ¼ .219) in LDH from preoperative (271.9 U/L,
95% CI 168.2–375.5 U/L) to postoperative (420.4 U/L,
95% CI 170.5–670.3 U/L) measurements. Mean corpuscu-
lar volume and mean corpuscular hemoglobin concentration
did not differ between preimplantation and postimplantation
measurements (data not shown).
Anticoagulation and Correlation With Thrombotic
Events
The mean international normalized ratio at the time
of blood sampling after Jarvik 2000 implantation was
FIGURE 3. Influence of rotation speed of Jarvik impeller pump on platelet
activation. To investigate influence of rotation speed of impeller pump on
platelets, expression of platelet activation marker P-selectin and glycopro-
tein IIb/IIIa activation (PAC-1) were determined by flow cytometry (fluores-
cence in arbitrary units, a.u.) in 1 patient with Jarvik 2000 assist device at
different rotational speeds. There were no increases in platelet activation
markers during stepwise increase in Jarvik impeller rotational speed from
8000 to 12,000 rpm. Data are shown as means and SEs of triplicate measure-
ments.
FIGURE 4. Levels of soluble P-selectin (P-sel) and soluble CD40L
(sCD40L) as markers of platelet activation in patients with Jarvik devices.
P-selectin is shed from platelet membrane during activation and therefore
indicates platelet activation status. There was no difference in plasma level
of soluble P-selectin after implantation of Jarvik 2000 relative to preopera-
tive values (P ¼ .53 by paired t test). CD40L is expressed on platelets on
activation and also shed from platelet surface, thereby becoming detectable
as soluble CD40L in plasma. There was no difference in plasma level of sol-
uble CD40L after implantation of Jarvik 2000 relative to preoperative
values (P ¼ .7 by paired t test). Data are depicted as means and SEs of 8
patients.
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P2.5  0.5. There was no obvious relationship between the
degree of anticoagulation and platelet activation in individ-
ual patients. One patient with a dissection of the thoracic
aorta who had only minimal anticoagulation because of
this fresh aortic dissection had an early debilitating stroke.
Taking into account that we did not observe any platelet
activation, the stroke was not correlated with platelet
activation.
DISCUSSION
Ventricular assist devices are used for treatment of end-
stage heart failure, either for bridging to transplant or for life-
time mechanical circulatory support. Assist devices may be
associated with major complications, however, including
thromboembolism. Axial rotary blood pumps are designed
to reduce complications because of their size.3,4 To provide
sufficient blood flow, however, an axial impeller pump with
high rotational speed has to be used, and there is concern that
such high speed could be associated with adverse platelet ac-
tivation. In our cohort of 8 Jarvik patients, we were unable to
demonstrate that the high rotational speed of the Jarvik 2000
impeller pump was associated with either platelet activation
or a loss of circulating platelets. In this context, however, it
should be taken into account that all patients investigated in
this study were receiving continuous aspirin treatment,
which may have had a protective effect on platelet function
against damage and activation by the impeller pump.
All rotary blood pumps seem to be associated with risks of
thrombosis and thromboembolism. The assist device Jarvik
2000 is placed directly in the left ventricle, and thus there is
no need for an inlet cannula. This decreases the potential for
blood stasis and thereby reduces the risk of thromboembolic
events.3 Although autopsy studies have revealed no throm-
botic apposition to the pump,7 thrombus formation within
the left ventricle has occasionally been reported.13 The posi-
tion of the outflow graft may also influence the incidence of
thromboembolism. There is no consensus regarding whether
to connect the outflow cannula to the ascending or descend-
ing thoracic aorta.11 The first provides better washout of the
aortic root, whereas the second reduces the risk of cerebral
thromboembolism, because small particles are less likely
to embolize to the brain.9 In addition to the administration
of anticoagulation therapy, the risk of stasis in the aortic
root may be lessened by minimizing pump flow to only un-
load the ventricle partially to allow opening of the aortic
valve. As another solution, a so-called intermittent low-
speed controller for this device has been released in Europe
to provide better aortic root washout. This controller auto-
matically reduces the pump speed every minute for a few
seconds to a low rotational setting, which leads to an in-
creased preload on the native heart and an ejection from
the native heart for a few heart beats.
The miniaturized pump design is based on a unique axial
impeller pump that revolves at extraordinarily high speeds of740 The Journal of Thoracic and Cardiovascular Su8000 to 12,000 rpm. Cellular blood components may
become activated or even damaged, however, by the me-
chanical forces caused by the impeller rotation. Indeed, de-
creased haptoglobin levels, mild increases in LDH and
plasma free hemoglobin levels have been reported after Jar-
vik implantation.2,8 indicating hemolysis and thus damage to
blood cells. In our study, we could confirm significantly re-
duced haptoglobin levels; however, we only saw a mild and
nonsignificant LDH increase and no decrease in circulating
platelet counts. Nevertheless, in this context platelets are still
of particular interest, because shear forces can induce plate-
let activation,5 resulting in a procoagulatory state and an in-
creased risk of thromboembolism. Therefore the question of
whether high rotational impeller speed, such as in the Jarvik
2000, activates platelets is important for the clinical use of all
rotary blood pumps and could also provide a rationale for the
use of platelet inhibitors.
One of the most reliable techniques to determine the plate-
let activation status is flow cytometry. On platelet activation,
P-selectin is mobilized from intracellular a-granula to the
platelet surface and can be detected by directly labeled
anti-CD62P antibodies. The determination of P-selectin ex-
pression on the platelet surface has been repeatedly used as
a marker of platelet activation in various experimental and
clinical settings.14,15 The conformational change of GP
IIb/IIIa from a low-affinity binding state for its ligand fibrin-
ogen to a high-affinity binding state is the final common
pathway of all types of platelet stimulation. The activated
GP IIb/IIIa receptor can be detected in flow cytometry
with the monoclonal immunoglobulin M antibody PAC-1,
an approach that has been extensively used for experimental
and clinical studies.16 In our study, both markers of platelet
activation, P-selectin expression and the high-affinity con-
formation of GP IIb/IIIa, did not demonstrate any activation
of circulating platelets in patients with the Jarvik 2000 assist
device. This finding is important in determining potential
prothrombotic properties of the Jarvik 2000. It indicates
that despite the high rotational speed of the impeller pump
of the Jarvik 2000, no activation of circulating platelets
was detectable by flow cytometry.
Soluble forms of platelet adhesion molecules are also
plasma markers of platelet activation. P-selectin and soluble
CD40L are both molecules that are mobilized to the platelet
cell membrane on platelet stimulation. Both molecules are
transmembranous molecules, and both are shed by cleavage
of the extracellular domain close to the transmembrane do-
main. The soluble parts of these molecules continue to cir-
culate in the blood and thus constitute a kind of measurable
memory of platelet activation. Indeed, both platelet activa-
tion markers have also been proved to be prognostically im-
portant in clinical settings, such as instable coronary artery
disease. Notably, especially in those patients with positive
results for soluble CD40L, antiplatelet therapy improved
overall prognosis.17 Our finding that the soluble markersrgery c March 2009
Lo¨ffler et al Cardiopulmonary Supportof platelet activation were not increased in Jarvik 2000 pa-
tients parallels the finding of our flow cytometric evaluation
of platelet activation and is another indicator that the Jarvik
2000 does not activate platelets in the clinical setting.
Favorable properties regarding platelet activation and he-
molysis have also recently been reported from a study in ju-
venile sheep that evaluated the function of the pediatric
Jarvik 2000 heart, in which the pump configuration was
adapted from its adult counterpart.18 After an initial maxi-
mum increase in LDH and plasma free hemoglobin levels
at 1 week after implantation, the degree of hemolysis stabi-
lized. The LDH level returned to baseline, and the plasma
free hemoglobin level stayed around 50% above baseline
throughout the remainder of the study period. This is quite
encouraging, especially considering that ovine red blood
cells are more fragile than are human red blood cells. Like-
wise, P-selectin expression on platelets followed a similar
pattern, with maximal effects 1 week after implantation
and normalization to minimal values by 2 weeks after
surgery.18
Our finding that platelet activation markers were not in-
creased after Jarvik 2000 implantation in patients receiving
low-dose aspirin therapy suggests that additional antiplatelet
therapy is not necessary for these patients. It is yet unclear
whether low-dose aspirin treatment, as administered to our
patients, inhibited some platelet activation associated with
a rotary blood pump. Aspirin, however, is not capable of
fully blocking platelet activation. Furthermore, our data ad-
dress the controversy regarding the clinical suitability of
high–rotational speed impeller pumps and indeed support
their use. Thus the enormous advantage that is provided
by the small size of high–rotational speed impeller pumps
does not appear to be counteracted by the activation of
platelets.
CONCLUSIONS
Despite the high rotational speed of the Jarvik 2000 left
ventricular assist device, no activation of circulating plate-
lets could be detected in patients receiving low-dose aspirin
therapy, even with sensitive methods including flow cytom-
etry and the determination of soluble platelet activation
markers. Overall, considering the major clinical benefits of
the Jarvik 2000 in terminal heart failure and our finding
that platelet activation was not associated with its use,
high–rotational speed impeller pumps such as that used in
the Jarvik 2000 represent a promising technology. The Jar-
vik 2000 and, potentially, similar rotary blood pumps do
not seem to be associated with platelet activation.The Journal of Thoracic and CWe thank Drs I. Ahrens and J. Martin for their help in obtaining
patient samples and Dr B. Balkau for advice regarding the statistical
analysis of the data presented in this article.
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